Advertisement

Present Situation and Prospect of Diagnosis and Treatment of Colorectal Cancer

  • Jianping Wang
Chapter

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors. The probability of suffering from colorectal cancer in a person’s life is 6 %. There are about 1.20 million new colorectal cancer cases in the world each year. Nearly 600,000 people die of colorectal cancer each year. Among all malignant tumors, both incidence and mortality of colorectal cancer are in the third position. In recent years, incidence and mortality of colorectal cancer in western-developed countries have decreased a little, whereas incidence of colorectal cancer in developing countries has still showed a rising trend [1].

Keywords

Colorectal Cancer Rectal Cancer Total Mesorectal Excision Local Recurrence Rate Fecal Occult Blood Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Sung JJ, Lau JY, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 2008;57:1166–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Lin C, Yang B, Donald M, et al. Cancer trends in Asian Pacific Rim Region. Tumor. 2004;24:422–6.Google Scholar
  3. 3.
    You WC, Jin F, Devesa S, et al. Rapid increase in colorectal cancer rates in urban Shanghai, 1972–97, in relation to dietary changes. J Cancer Epidemiol Prev. 2002;7:143–6.PubMedGoogle Scholar
  4. 4.
    Pfister DG, Benson AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350:2375–2.CrossRefPubMedGoogle Scholar
  5. 5.
    Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378–1.CrossRefPubMedGoogle Scholar
  6. 6.
    Shu Z, Hai Y, Gong Y, et al. Optimization of sequential screening scheme for colorectal cancer. Chinese Tumor. 1994;3:15–6.Google Scholar
  7. 7.
    Shinya H, Wolff WI. Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg. 1979;190:679–3.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88:819–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112:24–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Mak T, Lalloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. Br J Surg. 2004;91:790.CrossRefPubMedGoogle Scholar
  11. 11.
    Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA. 2004;291:1713–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Jianping W, Zuli Y, Yuanzhi T, et al. Effects of pelvic autonomic nerve preservation on male patients with rectal cancer. Chin J Pract Surg. 2003;23:44–6.Google Scholar
  13. 13.
    Jianping W, Huang M, Xinming S, et al. The assessment of curative effect after total mesorectal excision with autonomic nerve preservation for rectal cancer. Chin J Surg. 2005;43:1500–2.Google Scholar
  14. 14.
    Jianping W, Jun Z, Xinming S, et al. Analysis on pelvic autonomic nerve preservation in 120 female patients of rectal carcinoma undergoing radical resection. Chin J Gen Surg. 2005;20:619–21.Google Scholar
  15. 15.
    Jianping W, Guanfu C, Meijin H, et al. Influence of surgeon-related factors on postoperative sexual function in patients with rectal cancer. Chin J Pract Surg. 2005;25:688–9.Google Scholar
  16. 16.
    Ce Z, Zihai D, Guoxin L, et al. Anatomical observations of pelvic autonomic nerves concerning with total mesorectal excision. Chin J Clin Anat. 2006;24:60–4.Google Scholar
  17. 17.
    Willett CG, Compton CC, Shellito PC, Efird JT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer. 1994;73:2716–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Greenberg JA, Shibata D, Herndon JE, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008;51:1185–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236:522–30.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    McCall JL. Total mesorectal excision: evaluating the evidence. Aust N Z J Surg. 1997;67:599–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Kockerling F, Reymond MA, Altendorf-Hofmann A, et al. Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol. 1998;16:324–9.PubMedGoogle Scholar
  22. 22.
    Heald RJ, Smedh RK, Kald A, et al. Abdominoperineal excision of the rectum – an endangered operation. Norman Nigro Lectureship. Dis Colon Rectum. 1997;40:747–1.CrossRefPubMedGoogle Scholar
  23. 23.
    Carlsen E, Schlichting E, Guldvog I, et al. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg. 1998;85:526–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg. 2004;240:260–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356:93–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Martling A, Cedermark B, Johansson H, et al. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg. 2002;89:1008–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Martling A, Holm T, Rutqvist LE, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005;92:225–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Takahashi T, Ueno M, Azekura K, Ohta H. Lateral node dissection and total mesorectal excision for rectal cancer. Dis Colon Rectum. 2000;43:59–8.CrossRefGoogle Scholar
  29. 29.
    Xinshu D, Zhigao L, Binbin C, et al. Clinical significance of lateral lymphadenectomy in lower rectal cancer therapy. Chin J Bases Clin Gen Surg. 2003;10:103–4.Google Scholar
  30. 30.
    Grinnell RS. Lymphatic block with atypical and retrograde lymphatic metastasis and spread in carcinoma of the colon and rectum. Ann Surg. 1966;163:272–80.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg. 2008;95:33–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Xinshu D, Haitao X, Zhigao L, et al. Effect of lateral lymph nodes dissection and autonomic nerve preservation in anterior resection for rectal cancer: 124 cases review. Chin J Surg. 2007;45:1164–6.Google Scholar
  33. 33.
    Wan Y, Pan Y, Yucun L, et al. Patterns of lymph node metastasis and extent of lymph node dissection for middle or lower rectal cancer: analysis of 462. Chin J Surg. 2001;39:425–8.Google Scholar
  34. 34.
    Wan Y, Pan Y, Yucun L, et al. The characteristics of lateral node metastasis in middle/lower rectal cancer and its influence on the prognosis. Chin J Gastrointest Surg. 2004;7:104–6.Google Scholar
  35. 35.
    Fleshman JW, Nelson H, Peters WR, et al. Early results of laparoscopic surgery for colorectal cancer. Retrospective analysis of 372 patients treated by Clinical Outcomes of Surgical Therapy (COST) Study Group. Dis Colon Rectum. 1996;39:53–8.CrossRefGoogle Scholar
  36. 36.
    Nelson H, Sargent D, Wieand H, et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–9.CrossRefGoogle Scholar
  37. 37.
    Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6:477–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Buunen M, Veldkamp R, Hop WC, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009;10:44–2.CrossRefPubMedGoogle Scholar
  39. 39.
    Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Abraham NS, Young JM, Solomon MJ. Meta-analysis of short-term outcomes after laparoscopic resection for colorectal cancer. Br J Surg. 2004;91:1111–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Guillou P, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Leroy J, Jamali F, Forbes L, et al. Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes. Surg Endosc. 2004;18:281–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Minhua Z, Yanyan H, Aiguo L, et al. Clinical comparison of laparoscopic and open total mesorectal excision for lower rectal cancer. Chin J Gastrointest Surg. 2004;7:177–80.Google Scholar
  45. 45.
    Mei H, Zongguang Z, Wenzhang L, et al. Laparoscopic versus open total mesorectal excision with anal sphincter preservation for low rectal cancer: a randomized trial on short-term outcomes. Chin J Gastrointest Surg. 2003;6:368–71.Google Scholar
  46. 46.
    Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis. Surg Oncol. 2007;16:33–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12:165–2.CrossRefPubMedGoogle Scholar
  48. 48.
    Bengtsson G, Carlsson G, Hafstrom L, et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231:487–9.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Nagakura S, Shirai Y, Yokoyama N, et al. Major hepatic resection reduces the probability of intrahepatic recurrences following resection of colorectal carcinoma liver metastases. Hepatogastroenterology. 2003;50:779–3.PubMedGoogle Scholar
  51. 51.
    Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221:159–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Desen W. Adjuvant chemotherapy and neoadjuvant chemotherapy for colorectal cancer. In: Desen W, editor. Colorectal cancer. Beijing, China: Peking University Medical Press; p. 203–20.Google Scholar
  53. 53.
    Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879–7.PubMedGoogle Scholar
  54. 54.
    Haller D, Catalano P, Macdonald J, et al. Fluorouracil (FU), leucovorin and levamisole adjuvant therapy for colon cancer: five year report of INT-0089. Proc Am Soc Clin Oncol. 1998;17:256a.Google Scholar
  55. 55.
    Wolmark N, Colangelo L, Wieand S. National surgical adjuvant breast and bowel project trials in colon cancer. Semin Oncol. 2001;28:9–3.CrossRefPubMedGoogle Scholar
  56. 56.
    O’Connell MJ. North Central Cancer Treatment Group – Mayo Clinic trials in colon cancer. Semin Oncol. 2001;28:4–8.PubMedGoogle Scholar
  57. 57.
    Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553–60.CrossRefPubMedGoogle Scholar
  58. 58.
    Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347–3.CrossRefPubMedGoogle Scholar
  59. 59.
    Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008–5.CrossRefPubMedGoogle Scholar
  60. 60.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMedGoogle Scholar
  61. 61.
    Rodel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Van CE, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer. 2002;38:1429–6.CrossRefGoogle Scholar
  63. 63.
    Baddi L, Benson 3rd A. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist. 2005;10:325–1.CrossRefPubMedGoogle Scholar
  64. 64.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939–4.Google Scholar
  65. 65.
    Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999–5.CrossRefPubMedGoogle Scholar
  66. 66.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2.CrossRefPubMedGoogle Scholar
  67. 67.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–2.CrossRefPubMedGoogle Scholar
  69. 69.
    Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.CrossRefPubMedGoogle Scholar
  70. 70.
    Lievre A, Bachet JB, Le CD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11:6650–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht and People's Medical Publishing House 2017

Authors and Affiliations

  1. 1.Department of Colorectal SurgeryThe Sixth Affiliated Hospital, Sun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations